ArticleCureus2025
Refractory Ranula Following Surgery for Tongue Cancer: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The postoperative complications of tongue cancer include functional impairment due to tongue removal, sensory and taste disturbances due to damage to the lingual nerve, and intraoral ranula due to damage to the salivary gland duct in the lower part of the tongue. Surgical treatments, such as marsupialization, cystectomy, and sublingual adenectomy, have long been used to treat intraoral ranulae. Sclerotherapy with OK-432, which is less invasive than other treatments, has also recently been used. However, to the best of our knowledge, no case of sclerotherapy with OK-432 for ranulae resulting from postoperative complications of tongue cancer has been reported to date. In this report, we describe a case of a postoperative intraoral ranula that was treated several times with sclerotherapy using OK-432; however, the ranula recurred. Therefore, we performed marsupialization and obtained satisfactory results. A man in his 60s underwent partial tongue resection for right-sided tongue cancer (T2N0M0). The resected area was then covered with polyglycolic acid sheets and fibrin glue. Seven months after surgery, a well-defined, soft, blue-violet mass measuring 38 × 26 mm was observed at the resection site. Contrast-enhanced magnetic resonance imaging (MRI) of the head and neck revealed a cystic high-signal area suggestive of fluid collection in the right sublingual space on T2-weighted images. Local and imaging findings were consistent with those of the right intraoral ranula. OK-432 1 KE/0.2 ml was then injected into the right ranula. After the injection, a temporary resolution was observed; however, an increase in the size of the recurring ranula was noted. Therefore, three OK-432 injections were administered. However, owing to recurrent findings of the ranula in the same area, right-sided ranula marsupialization was performed under general anesthesia five months after the first OK-432 injection. The surgical field performs a tie-over. Contrast-enhanced MRI was performed three months after marsupialization to confirm the absence of recurrence or metastasis of the ranula or tongue cancer. Currently, 12 months after surgery, no recurrence or adverse events have been observed in either the tongue cancer or the ranula. Our case revealed that sclerotherapy with OK-432 is not effective for ranula, which is a postoperative complication of tongue cancer. In such cases, surgical treatments such as marsupialization may be appropriate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.